Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2^nd Annual Autoimmune & Inflammatory Disease Virtual Conference.

• Thursday, March 28^th, Remy Durand, Ph.D., Chief Business Officer at Alpine, will participate in a fireside chat at 3:00 pm ET/12:00 pm PT and the Company will host investor meetings the same day.

Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, www.alpineimmunesciences.com visit. Follow @AlpineImmuneSci on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240320830092/en/

The Alpine Immune Sciences Stock at the time of publication of the news with a raise of +0,48 % to 40,14EUR on Nasdaq stock exchange (20. März 2024, 21:00 Uhr).